Table 3.
Sensitivity and specificity of biomarkers, singly or in combination, with regard to brain metastases in Luminal and non-Luminal patients.
| Patients (N = 208) | ||||||
|---|---|---|---|---|---|---|
| Biomarker | Luminal group (N = 141) |
Non-Luminal group (N = 67) |
||||
| Nb | Sensitivity (%) | Specificity (%) | Nb | Sensitivity (%) | Specificity (%) | |
| FN14 | 138 | (53.85) | (89.60) | 65 | (31.58) | (88.89) |
| GRP94 | 139 | (76.92) | (55.56) | 66 | (57.89) | (60.71) |
| Her2 | 141 | (46.15) | (89.84) | 67 | (30.77) | (67.86) |
| FN14 + GRP94a | 139 | (84.62) | (50.00) | 66 | (68.42) | (57.14) |
| FN14 + GRP94 + Her2a | 139 | (84.62) | (45.24) | 67 | (71.79) | (42.86) |
aIn each case, these combinations were considered positive when at least one of the assessed molecules was positive and negative when all of them were negative.
bDifferences in number or patients (N) are due to those patients whose biomarker assessment (singly or in combination) was unknown.